By Chemical Treatment Patents (Class 435/238)
  • Patent number: 10087214
    Abstract: Provided herein are methods of performing chromatography with gamma-irradiated chromatography resin that include providing a chromatography column including a gamma-irradiated chromatography resin; performing a first cycle of chromatography through the column, where the cycle includes exposing the chromatography resin to a denaturing buffer; and performing at least one additional cycle of chromatography through the column. Also provided are integrated, closed or substantially closed, and continuous processes for manufacturing of a recombinant protein that include the use of at least one chromatography column including gamma-irradiated chromatography resin, where the gamma-irradiated chromatography resin is exposed to denaturing buffer during each cycle in the process, and reduced bioburden buffer is used in the process.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 2, 2018
    Assignee: Genzyme Corporation
    Inventors: Rahul Godawat, Veena Warikoo, Rohan Patil, Konstantin Konstantinov, Venkat Kishore Ryakala, Mahsa Rohani
  • Patent number: 10072256
    Abstract: Processes for separating an infectious viral load from a pancreatin sample and for quantitatively determining the viral load in a pancreatin sample are described herein.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: September 11, 2018
    Assignee: ABBOTT PRODUCTS GMBH
    Inventors: Frauke Busse, Martin Frink, Dietmar Becher, Leopold Doehner
  • Patent number: 9642937
    Abstract: The present invention provides a preparation method for implantable medical biological material of animal origin comprising the following procedures: Pre-processing, and washing of animal tissue materials; inactivation of virus; decellularizing cell; sodium chloride processing; molding and packaging sterilization. Cell-free ECM materials of animal origin produced by this method can achieve the goal of completely removing cell components of animal origin and composition of DNA, and at the same time, the natural ECM composition, three-dimensional structure and active growth factor which can induce and promote tissue regeneration retain. By using this process, endotoxin, organic solvents and toxic solvent residue are thus omitted and products with different sizes, thickness and mechanical strength can be formed.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: May 9, 2017
    Assignee: BEIJING BIOSIS HEALING BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventors: Bo Zhao, Zhenjun Wang
  • Patent number: 9636363
    Abstract: Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2?-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4?, 5?-dichloro-benzoic acid methyl ester hydrochloride.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: May 2, 2017
    Assignee: Kiadis Pharma Canada Inc.
    Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
  • Patent number: 9416362
    Abstract: Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: August 16, 2016
    Assignee: The Board of Trustees of The Leland Stanford Junior University
    Inventors: Peter Sarnow, Catherine L. Jopling, Alissa M. Lancaster
  • Patent number: 9200281
    Abstract: Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: December 1, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Catherine J Pachuk, Chandrasekhar Satishchandran, Vincent R. Zurawski, Liat Mintz
  • Publication number: 20150133636
    Abstract: The present invention relates to improved processes and systems for purification of biological molecules, where the processes can be performed in a continuous manner.
    Type: Application
    Filed: June 21, 2013
    Publication date: May 14, 2015
    Inventors: Alex Xenopoulos, Michael Phillips, Wilson Moya, Jad Jaber, Mikhail Kozlov, Ajish Potty, Matthew T. Stone, William Cataldo, Christopher Gillespie
  • Publication number: 20150119411
    Abstract: Described herein are compounds, pharmaceutical compositions and methods for treating a respiratory syncytial virus infection in a subject, or for inhibiting replication of respiratory syncytial virus.
    Type: Application
    Filed: June 5, 2013
    Publication date: April 30, 2015
    Inventors: Jennifer E. Golden, Jeffrey Aube, Denise S. Simpson, Daniel P. Flaherty, Daljit S. Matharu, William E. Severson, Lynn Rasmussen
  • Publication number: 20150110794
    Abstract: This disclosure provides anti-human cytomegalovirus antibodies and methods of treatment, prophylaxis, detection, and diagnosis using the same. In another aspect, the disclosure features therapeutic, prophylactic, and/or diagnostic compositions for human cytomegalovirus infection or for a human cytomegalovirus-related disease that include a binding agent (e.g., antibody) or polynucleotide disclosed herein. In some embodiments, the composition is formulated for ocular or topical administration. The compositions can further include one or more human cytomegalovirus-neutralizing antibodies, an intravenous immunoglobulin preparation, and/or one or more antiviral compounds (e.g., ganciclovir, foscamet, cidofovir, or valganciclovir).
    Type: Application
    Filed: April 30, 2013
    Publication date: April 23, 2015
    Inventors: Shuji Sato, Sean Andre Beausoleil, Wan Cheung Cheung, Roberto D. Polakiewicz
  • Publication number: 20150104849
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 16, 2015
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Publication number: 20150094327
    Abstract: The invention provides a fluorescence polarization (FP)-based assay to identify inhibitors of resolvase's DNA cleavage activity. The invention also provides resolvase inhibitors identified by the assay, as well as derivatives and analogs thereof. In certain embodiments, the compounds of the invention are useful to treat a poxvirus infection in an infected subject.
    Type: Application
    Filed: April 29, 2013
    Publication date: April 2, 2015
    Inventors: Frederic D. Bushman, Young Hwang, Matt Culyba
  • Patent number: 8980610
    Abstract: The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodiments, inactivation or reduction of viral titers by exposure to arginine is achieved in a neutral (pH ˜7) or near neutral (˜pH 6 to ˜pH 8) environment.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: March 17, 2015
    Assignee: Biogen Idec MA Inc.
    Inventors: Keith Selvitelli, Justin McCue
  • Publication number: 20150072982
    Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 12, 2015
    Inventors: Robert Than Hendricks, Leonid Beigelman, David Bernard Smith, Antitsa Dimitrova Stoycheva
  • Publication number: 20150065458
    Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 5, 2015
    Inventors: Thierry PELET, Donald F. H. Wallach
  • Publication number: 20150064768
    Abstract: The present invention provides a closed system to propagate virus-infected cells without the effect of shear force, while providing quicker access to nutrients than is available conventionally. This system design allows for a high density of infected cell growth to increase the virus yields and to maintain homogeneity of the contents of the main container. The system further provides a nuclease to degrade the cellular DNA prior for purification of the virus or viral components. As the system is designed for maximum containment at low risk, the live virus can be a hazardous virus such as a Bio-safety Level 3 (BSL 3), BSL 4 or BSL5 virus.
    Type: Application
    Filed: April 5, 2013
    Publication date: March 5, 2015
    Inventor: Subhash V. KAPRE
  • Publication number: 20150065504
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: August 19, 2014
    Publication date: March 5, 2015
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He, Karin Ann Stein
  • Publication number: 20150064769
    Abstract: The present application relates to novel and improved methods of achieving virus inactivation during a protein purification process.
    Type: Application
    Filed: June 13, 2013
    Publication date: March 5, 2015
    Inventor: Alex Xenopoulos
  • Publication number: 20150056164
    Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 26, 2015
    Applicant: AbbVie Inc.
    Inventors: David A. Betebenner, John K. Pratt, David A. DeGoey, Pamela L. Donner, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Kenton L. Longenecker, Clarence J. Maring, John T. Randolph, Todd W. Rockway, Michael D. Tufano, Rolf Wagner, Dachun Liu
  • Publication number: 20150050713
    Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    Type: Application
    Filed: July 25, 2014
    Publication date: February 19, 2015
    Inventors: Michael P. Malakhov, Fang Fang
  • Patent number: 8940517
    Abstract: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: January 27, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Michael Graninger, Martin Kaliwoda
  • Publication number: 20150010566
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: December 3, 2012
    Publication date: January 8, 2015
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • Publication number: 20150010505
    Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I).
    Type: Application
    Filed: February 8, 2013
    Publication date: January 8, 2015
    Applicant: LUPIN LIMITED
    Inventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20140363518
    Abstract: Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about ?20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant.
    Type: Application
    Filed: May 20, 2014
    Publication date: December 11, 2014
    Applicant: Biopep Solutions, Inc.
    Inventors: Abbas Mohammad Ghawi, Ahmed Merzouk, Abdualrahman Abdualkader, Mohamed Alaama
  • Patent number: 8889398
    Abstract: The present invention relates generally to the field of prevention of diseases caused by enveloped viruses. More particularly, this invention concerns a composition for inactivating an enveloped virus comprising at least one non phospholipid Lipid Vesicle (nPLV) able to interact with said enveloped virus and an agent that enhances the lipid exchange between said nPLV and the membrane of said enveloped virus.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: November 18, 2014
    Assignee: Viroblock SA
    Inventors: Thierry Pelet, Francesca A. Wallach
  • Publication number: 20140328795
    Abstract: In an embodiment of the present disclosure there is provided a method of inactivating enveloped DNA virus particles in a biological sample. In an embodiment, such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182 In some embodiments, the DNA virus is the Herpes Simplex virus-1 (HSV-1) or the Herpes Simplex Virus-2 (HSV-2). In another embodiment of the present disclosure, there is provided a method of treating, preventing, or reducing a viral infection caused by an enveloped DNA virus in a subject in need thereof. In yet another embodiment, there is provided a method of preventing transmission of a viral infection to a subject in need thereof.
    Type: Application
    Filed: September 10, 2013
    Publication date: November 6, 2014
    Applicants: The Texas A&M University System, The Scripps Research Institute
    Inventors: Zhilei Chen, Karrupiah Chockalingam, Ana M. Chamoun-Emanuelli, Rudo Simeon, Michael Bobardt, Philippe Gallay
  • Publication number: 20140323392
    Abstract: Disclosed herein are compositions and methods for inhibiting viral entry.
    Type: Application
    Filed: March 28, 2012
    Publication date: October 30, 2014
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: J. Nicholas Francis, Joseph S. Redman, Michael S. Kay
  • Publication number: 20140315277
    Abstract: The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuclease and ii) a DNA alkylating agent.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 23, 2014
    Applicant: GlaxoSmithKline Biologicals s. a.
    Inventors: Bruno Rene ANDRE, Benoit Paul Suzanne Champluvier, Benedicte Van Der Hayden
  • Publication number: 20140256019
    Abstract: The present invention provides compositions and methods for treating or preventing viral infections.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: RECOPHARMA AB
    Inventor: Jan Holgersson
  • Publication number: 20140227335
    Abstract: In some embodiments the present disclosure provides a method of inactivating a RNA virus of the family retroviridae in a biological sample. Such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182. In an embodiment of the present disclosure the RNA virus is selected from the group consisting of HIV pseudotyped lentiviruses, primary human immunodeficiency virus-1 isolates (HIV-1), human immunodeficiency virus-2 (HIV-2), and simian immunodeficiency virus (SIV). Further embodiments of the present disclosure pertain to a method of treating a subject infected by a RNA virus of the family retroviridae. Another embodiment of the present invention pertains to a method of preventing transmission of a RNA virus of the family retroviridae in a subject in need thereof.
    Type: Application
    Filed: September 10, 2013
    Publication date: August 14, 2014
    Inventors: Zhilei Chen, Karrupiah Chockalingam, Ana M. Chamoun-Emanuelli, Rudo Simeon, Michael Bobardt, Philippe Gallay
  • Publication number: 20140227765
    Abstract: Certain embodiments are directed to Negevirus and their polynucleotides and polypeptides.
    Type: Application
    Filed: November 21, 2013
    Publication date: August 14, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Farooq Nasar, Rodion V. Gorchakov, Andrew D. Haddow, Robert B. Tesh, Hilda Guzman, Scott C. Weaver
  • Publication number: 20140206639
    Abstract: The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or cancer cell. The dihydro base may be used to reduce DNA methylation (e.g., in a cancer cell). The present invention also provides kits including the inventive pharmaceutical compositions and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis C) or cancer using the pharmaceutical compositions or kits.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 24, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: John M. Essigmann, Deyu Li, Katherine J. Silvestre
  • Publication number: 20140205628
    Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
    Type: Application
    Filed: December 16, 2013
    Publication date: July 24, 2014
    Applicant: WORLD FORCE TECHNOLOGIES, LLC
    Inventors: Thomas W. Konowalchuk, Jack Konowalchuk
  • Patent number: 8784838
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 22, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 8778263
    Abstract: The invention relates to an irradiation apparatus for inactivating pathogens and/or leukocytes in a biological fluid such as a platelet suspension and/or plasma comprising: a casing (2), a support member (3) for carrying at least one irradiation bag (19) containing the biological fluid, a light source (4) comprising two banks of light (5, 6) disposed above and below the support member (3), and an agitating system (25) for moving the support member (3), the light source generating UVC light of suitable intensity to inactivate pathogens and/or leukocytes and the agitation system moving the support member in an orbital path with predetermined amplitude and rotational frequency suitable to expose the whole biological fluid to UVC.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: July 15, 2014
    Assignee: Maco Pharma S.A.
    Inventors: Wolfram Hubert Walker, Frank Tolksdorf, Thierry Verpoort, Francis Goudaliez, Maurice Behague, Arnaud Chavatte
  • Patent number: 8778653
    Abstract: A method for purification of viral compositions is provided. In particular, a method for reduction of unwanted residual DNA in a viral composition while retaining the immunogenicity of the virus itself is provided. The resulting immunogenic viral composition is substantially free of residual DNA, and is useful for the manufacture of medical products, such as vaccines designed for human or animal.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: July 15, 2014
    Assignee: Yisheng Biopharma Holdings Ltd.
    Inventors: Yi Zhang, Jinming Dai, Yajin Ni
  • Patent number: 8765141
    Abstract: We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: July 1, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Aida E. Rieder, Luis L. Rodriguez, Jason R. Hollister, Sabena Uddowla
  • Publication number: 20140179637
    Abstract: A compound having an antiviral activity for inhibiting release of an enveloped virus from a cell is disclosed, including methods of inhibiting release of an enveloped virus from a cell. The antiviral activity of the compound includes inhibiting formation of an associative complex or disrupting formation of an associative complex. The associative complex comprises an L-domain motif of the enveloped virus and at least one cellular polypeptide, or fragment thereof, capable of binding the L-domain motif of the enveloped virus.
    Type: Application
    Filed: December 21, 2013
    Publication date: June 26, 2014
    Applicants: The Research Foundation for The State University of New York, Northwestern University
    Inventors: Jonathan Leis, Carol Carter
  • Patent number: 8716000
    Abstract: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: May 6, 2014
    Assignee: Oregon Health and Science University
    Inventors: Mark K. Slifka, Shirley Villadiego, Erika Hammarlund, Paul Yoshihara
  • Publication number: 20140088184
    Abstract: The present invention relates to a flavonoid compound having the formula I, where R3, R5 and/or R7 is a group having the formula II, or R1 and R2 are both OH groups, or to one of the pharmaceutically acceptable salts or esters thereof, for use as an antiviral agent in the treatment and/or prevention of a hepatitis C virus (HCV) infection. The invention also relates to an ex vivo method for reducing the infectivity of HCV or for inactivating HCV, including a step of contacting said hepatitis C virus with a compound having the formula (I).
    Type: Application
    Filed: March 28, 2012
    Publication date: March 27, 2014
    Applicants: INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Karin Seron, Jean Dubuisson, Yves Rouille, Czeslaw Wychowski
  • Publication number: 20140080177
    Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.
    Type: Application
    Filed: August 20, 2013
    Publication date: March 20, 2014
    Applicant: Pieris AG
    Inventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
  • Publication number: 20140080114
    Abstract: The present invention is directed to methods, kits and compositions for inactivating viral agents in or on articles including blood based products and feature a light sensitive compound selected from the group consisting of hypericin, pseudohypericin and hypocrellin, and a group of light producing compounds comprising luciferase, luciferin and ATP.
    Type: Application
    Filed: September 6, 2013
    Publication date: March 20, 2014
    Applicant: APHIOS CORPORATION
    Inventors: Trevor Percival CASTOR, Vasudeyacharya JAYARAMA
  • Publication number: 20140066396
    Abstract: The invention is directed to a method of treating infections by hepatitis C virus by administering N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide and one or more additional antiviral compounds or pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 6, 2014
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Peter S. Dragovich, Peggy A. Thompson, Frank Ruebsam
  • Publication number: 20140057948
    Abstract: The present invention relates, e.g., to a method for inhibiting infectivity of a lentivirus (e.g., a lentivirus which expresses a Viral infectivity factor (Vif) protein), such as, e.g., SIV, SHIV and/or HIV, comprising contacting a cell which is producing the virus with an antiviral-effective amount of a membrane-permeable Zinc (Zn) chelator, wherein the antiviral-effective amount of the Zn chelator does not substantially inhibit proteins in the cell which contain Zn-binding motifs other than lentivirus Vif. Kits and pharmaceutical compositions are also disclosed, as is a method for identifying inhibitors of lentiviruses that target a specific zinc-binding motif of the lentivirus Vif protein.
    Type: Application
    Filed: December 11, 2012
    Publication date: February 27, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Xiao-Fang Yu, Elana S. Erhlich, Xiao Zuoxiang
  • Publication number: 20140050761
    Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 20, 2014
    Inventors: Eric Bergeron, Scott Dusan Pegan, Stuart T. Nichol, Michelle Kay Deaton
  • Publication number: 20140044752
    Abstract: The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. Preferably, the formaldehyde donor agent is selected from a non-crosslinking chemical fixative that contains urea.
    Type: Application
    Filed: May 3, 2012
    Publication date: February 13, 2014
    Applicant: STRECK, INC.
    Inventors: Wayne L. Ryan, James A Grunkemeyer
  • Publication number: 20140038919
    Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: December 16, 2011
    Publication date: February 6, 2014
    Applicant: AbbVie Inc.
    Inventors: Clarence J. Maring, John K. Pratt, William A. Carroll, Dachun Liu, David A. Betebenner, Douglas K. Hutchinson, Michael D. Tufano, Todd W. Rockway, Uwe Schoen, Axel Pahl, Andreas Witte
  • Publication number: 20140038168
    Abstract: The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 6, 2014
    Applicant: KFLP BIOTECH, LLC
    Inventors: Andrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
  • Publication number: 20140031346
    Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is CR3, and A is and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich
  • Publication number: 20140018379
    Abstract: The present invention provides a compound of Formula I or Formula VI: as defined herein. The invention is also directed to compositions comprising the compound of Formula I or Formula VI and methods of therapeutic treatment using the compound of Formula I or Formula VI.
    Type: Application
    Filed: February 18, 2011
    Publication date: January 16, 2014
    Applicant: CONCERT PHARMACEUTICALS INC.
    Inventors: Roger Tung, Craig E. Masse
  • Publication number: 20140005192
    Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    Type: Application
    Filed: June 14, 2013
    Publication date: January 2, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, Michael P. Clark, Upul K. Bandarage, Ioana Davies, John P. Duffy, Huai Gao, Jun Feng, Jianglin Liang, Joseph M. Kennedy, Mark W. Ledeboer, Brian Ledford, Francois Maltais, Emanuele Perola